Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
<h4>Background</h4> <p>The ability to predict recurrence and survival after neoadjuvant chemotherapy (NAC) and surgery for oesophageal cancer remains elusive. This study evaluated the role of [18F]fluorodeoxyglucose (FDG) PET–CT in assessing tumour and nodal response as a prognost...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2017
|
| _version_ | 1826258760985739264 |
|---|---|
| author | Findlay, J Bradley, K Wang, L Franklin, J Teoh, E Gleeson, F Maynard, N Gillies, R Middleton, M |
| author_facet | Findlay, J Bradley, K Wang, L Franklin, J Teoh, E Gleeson, F Maynard, N Gillies, R Middleton, M |
| author_sort | Findlay, J |
| collection | OXFORD |
| description | <h4>Background</h4> <p>The ability to predict recurrence and survival after neoadjuvant chemotherapy (NAC) and surgery for oesophageal cancer remains elusive. This study evaluated the role of [18F]fluorodeoxyglucose (FDG) PET–CT in assessing tumour and nodal response as a prognostic marker.</p> <h4>Methods</h4> <p>This was a single-centre UK cohort study. From 2006 to 2014, patients with oesophageal cancer staged with PET–CT before NAC, and restaged by CT or PET–CT before resection, were included. Pathological tumour response was evaluated using Mandard regression grades. Metabolic tumour and nodal responses (mTR and mNR respectively) were quantified using absolute and threshold reductions.</p> <h4>Results</h4> <p>Among 294 included patients, mTR and mNR independently predicted prognosis before surgery. After surgery, mNR (but not mTR), pathological tumour response, resection margin status and pathological node category predicted prognosis. Patients with FDG-avid nodal disease after NAC were at high risk of recurrence/death at 1 and 2 years (43 and 71 per cent respectively; P =0⋅030 and P =0⋅025 versus patients without avid nodes), and had a worse prognosis than patients with non-avid nodal metastases: hazard ratio 4⋅19 (95 per cent c.i. 1⋅87 to 9⋅40) and 2⋅11 (1⋅12 to 3⋅97) respectively versus patients without nodal metastases. Considering mTR and mNR response separately improved prognostication.</p> <h4>Conclusion</h4> <p>mNR is a novel prognostic factor, independent of conventional N status. Primary and nodal tumours may respond discordantly and patients with FDG-avid nodes after NAC have a poor prognosis.</p> |
| first_indexed | 2024-03-06T18:39:06Z |
| format | Journal article |
| id | oxford-uuid:0c47f6d6-45ca-4d6d-88ba-411a920a6528 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:39:06Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:0c47f6d6-45ca-4d6d-88ba-411a920a65282022-03-26T09:34:04ZMetabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0c47f6d6-45ca-4d6d-88ba-411a920a6528EnglishSymplectic Elements at OxfordWiley2017Findlay, JBradley, KWang, LFranklin, JTeoh, EGleeson, FMaynard, NGillies, RMiddleton, M <h4>Background</h4> <p>The ability to predict recurrence and survival after neoadjuvant chemotherapy (NAC) and surgery for oesophageal cancer remains elusive. This study evaluated the role of [18F]fluorodeoxyglucose (FDG) PET–CT in assessing tumour and nodal response as a prognostic marker.</p> <h4>Methods</h4> <p>This was a single-centre UK cohort study. From 2006 to 2014, patients with oesophageal cancer staged with PET–CT before NAC, and restaged by CT or PET–CT before resection, were included. Pathological tumour response was evaluated using Mandard regression grades. Metabolic tumour and nodal responses (mTR and mNR respectively) were quantified using absolute and threshold reductions.</p> <h4>Results</h4> <p>Among 294 included patients, mTR and mNR independently predicted prognosis before surgery. After surgery, mNR (but not mTR), pathological tumour response, resection margin status and pathological node category predicted prognosis. Patients with FDG-avid nodal disease after NAC were at high risk of recurrence/death at 1 and 2 years (43 and 71 per cent respectively; P =0⋅030 and P =0⋅025 versus patients without avid nodes), and had a worse prognosis than patients with non-avid nodal metastases: hazard ratio 4⋅19 (95 per cent c.i. 1⋅87 to 9⋅40) and 2⋅11 (1⋅12 to 3⋅97) respectively versus patients without nodal metastases. Considering mTR and mNR response separately improved prognostication.</p> <h4>Conclusion</h4> <p>mNR is a novel prognostic factor, independent of conventional N status. Primary and nodal tumours may respond discordantly and patients with FDG-avid nodes after NAC have a poor prognosis.</p> |
| spellingShingle | Findlay, J Bradley, K Wang, L Franklin, J Teoh, E Gleeson, F Maynard, N Gillies, R Middleton, M Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. |
| title | Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. |
| title_full | Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. |
| title_fullStr | Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. |
| title_full_unstemmed | Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. |
| title_short | Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. |
| title_sort | metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer |
| work_keys_str_mv | AT findlayj metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT bradleyk metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT wangl metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT franklinj metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT teohe metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT gleesonf metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT maynardn metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT gilliesr metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer AT middletonm metabolicnodalresponseasaprognosticmarkerafterneoadjuvanttherapyforoesophagealcancer |